Neovacs

Focus: Neovacs is a France-based biotechnology company specializing in cytokine immunotherapy for autoimmune and chronic inflammatory diseases. The company operates as a clinical-stage biotech with a focused pipeline in kinoid-based therapeutics.

Auto-immune diseases Auto-immune diseases, Chronic inflammatory diseases

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Neovacs

AI assessmentNot Hiring

No open roles listed right now. Follow Neovacs to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IFN-K

Systemic Lupus Erythematosus

Phase 1/2

Clinical Trials (1)

NCT01058343Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Phase 1/2

Help build intelligence for Neovacs

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on novel kinoid platform technology targeting validated cytokine pathways (TNFα, IFN) across multiple autoimmune indications
Early-stage company offers hands-on involvement in clinical development with 7 active trials spanning Phase 1/2 and Phase 2
Specialized focus in high-unmet-need autoimmune space (Crohn's, RA, SLE, dermatomyositis) with limited competitive kinoid approaches

Watch Out For

Pre-revenue biotech with unknown funding status and financial stability; cash runway and burn rate not disclosed
Minimal hiring activity (only 2 open positions) signals limited growth trajectory or constrained resources for team expansion

Generated by Claude from Neovacs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TNFa Kinoid

Crohn's Disease

Phase 1/2

Clinical Trials (1)

NCT00808262Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Phase 1/2

TNFa Kinoid

Rheumatoid Arthritis

Phase 2

Clinical Trials (1)

NCT01040715Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists

Phase 2